Targeting epigenetic mediators of gene expression in thoracic malignancies

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1819, Issue 7, 2012, Pages 836-845

  Schrump, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trials; Epigenetics; Esophageal cancer; Lung cancer; Mesothelioma; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEPSIPEPTIDE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; FLAVOPIRIDOL; HISTAMINE METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; PACLITAXEL; POLYCOMB GROUP PROTEIN; ROMIDEPSIN; VORINOSTAT;

ALLELE; APOPTOSIS; ASBESTOS BODY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; CIGARETTE SMOKING; CLONOGENESIS; CONTINUOUS INFUSION; CPG ISLAND; CYTOTOXICITY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DNA ADDUCT; DNA DAMAGE; DNA METHYLATION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; HETEROCHROMATIN; HISTOLOGY; HISTONE ACETYLATION; HISTONE CODE; HISTONE MODIFICATION; HISTONE UBIQUITINATION; HUMAN; IMMUNOGENICITY; LUNG CANCER; LUNG CARCINOGENESIS; LUNG RESECTION; LYMPH NODE METASTASIS; MITOSIS SPINDLE; MULTIPLE CYCLE TREATMENT; NUCLEOSOME; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SENESCENCE; SMOKING; SQUAMOUS CELL CARCINOMA; SUMOYLATION; THORAX CANCER; THYMOMA; TUMOR REGRESSION; UPREGULATION; X CHROMOSOME INACTIVATION;

ANIMALS; CHROMATIN; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR TARGETED THERAPY; POLYCOMB-GROUP PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; THORACIC NEOPLASMS;

EID: 84861916556     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2012.03.009     Document Type: Review

References (192)

1. Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 2008, 57:1226.
2. Akcakanat A., Kanda T., Tanabe T., Komukai S., Yajima K., Nakagawa S., Ohashi M., Hatakeyama K. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int. J. Cancer 2006, 118:123.
3. Alvarez H., Opalinska J., Zhou L., Sohal D., Fazzari M.J., Yu Y., Montagna C., Montgomery E.A., Canto M., Dunbar K.B., Wang J., Roa J.C., Mo Y., Bhagat T., Ramesh K.H., Cannizzaro L., Mollenhauer J., Thompson R.F., Suzuki M., Meltzer S.J., Melnick A., Greally J.M., Maitra A., Verma A. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 2011, 7:e1001356.
4. Atanackovic D., Hildebrandt Y., Jadczak A., Cao Y., Luetkens T., Meyer S., Kobold S., Bartels K., Pabst C., Lajmi N., Gordic M., Stahl T., Zander A.R., Bokemeyer C., Kroger N. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010, 95:785.
5. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381.
6. Barlesi F., Giaccone G., Gallegos-Ruiz M.I., Loundou A., Span S.W., Lefesvre P., Kruyt F.A., Rodriguez J.A. Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 2007, 25:4358.
7. Barth T.K., Imhof A. Fast signals and slow marks: the dynamics of histone modifications. Trends Biochem. Sci. 2010, 35:618.
8. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726.
9. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 2010, 19:698.
10. Berndsen C.E., Denu J.M. Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr. Opin. Struct. Biol. 2008, 18:682.
11. Bowman R.V., Wright C.M., Davidson M.R., Francis S.M., Yang I.A., Fong K.M. Epigenomic targets for the treatment of respiratory disease. Expert Opin. Ther. Targets 2009, 13:625.
12. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323.
13. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 2010, 6:238.
14. Brambilla E., Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur. Respir. J. 2009, 33:1485.
15. Brock M.V., Gou M., Akiyama Y., Muller A., Wu T.T., Montgomery E., Deasel M., Germonpre P., Rubinson L., Heitmiller R.F., Yang S.C., Forastiere A.A., Baylin S.B., Herman J.G. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin. Cancer Res. 2003, 9:2912.
16. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., Glockner S., Piantadosi S., Gabrielson E., Pridham G., Pelosky K., Belinsky S.A., Yang S.C., Baylin S.B., Herman J.G. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 2008, 358:1118.
17. Brueckner B., Kuck D., Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007, 13:17.
18. Bruzzese F., Rocco M., Castelli S., Di G.E., Desideri A., Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol. Cancer Ther. 2009, 8:3075.
19. Buckingham L., Penfield F.L., Kim A., Liptay M., Barger C., Basu S., Fidler M., Walters K., Bonomi P., Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int. J. Cancer 2010, 126:1630.
20. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009, 100:2014.
21. Campbell P.M., Bovenzi V., Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 2004, 25:499.
22. Carrasco J., Van P.A., Neyns B., Lethe B., Brasseur F., Renkvist N., van der Bruggen P., van B.N., Paulus R., Thielemans K., Boon T., Godelaine D. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 2008, 180:3585.
23. Chai G., Li L., Zhou W., Wu L., Zhao Y., Wang D., Lu S., Yu Y., Wang H., McNutt M.A., Hu Y.G., Chen Y., Yang Y., Wu X., Otterson G.A., Zhu W.G. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 2008, 3:e2445.
24. Chen C., Zhao M., Yin N., He B., Wang B., Yuan Y., Yu F., Hu J., Yin B., Lu Q. Abnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. Cancer Investig. 2011, 29:548.
25. Chen M.W., Hua K.T., Kao H.J., Chi C.C., Wei L.H., Johansson G., Shiah S.G., Chen P.S., Jeng Y.M., Cheng T.Y., Lai T.C., Chang J.S., Jan Y.H., Chien M.H., Yang C.J., Huang M.S., Hsiao M., Kuo M.L. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010, 70:7830.
26. Chen Y.T., Hsu M., Lee P., Shin S.J., Mhawech-Fauceglia P., Odunsi K., Altorki N.K., Song C.J., Jin B.Q., Simpson A.J., Old L.J. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int. J. Cancer 2009, 124:2893.
27. Chen Z., Zhu B., Wu Y. Expression of TRAG-3 antigen in non-small-cell lung carcinomas. Lung Cancer 2002, 38:101.
28. Chinnasamy N., Wargo J.A., Yu Z., Rao M., Frankel T.L., Riley J.P., Hong J.J., Parkhurst M.R., Feldman S.A., Schrump D.S., Restifo N.P., Robbins P.F., Rosenberg S.A., Morgan R.A. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 2011, 186:685.
29. Choi S.H., Heo K., Byun H.M., An W., Lu W., Yang A.S. Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res. 2011, 39:104-118.
30. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834.
31. Christensen B.C., Godleski J.J., Marsit C.J., Houseman E.A., Lopez-Fagundo C.Y., Longacker J.L., Bueno R., Sugarbaker D.J., Nelson H.H., Kelsey K.T. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008, 29:1555.
32. Christensen B.C., Houseman E.A., Poage G.M., Godleski J.J., Bueno R., Sugarbaker D.J., Wiencke J.K., Nelson H.H., Marsit C.J., Kelsey K.T. Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res. 2010, 70:5686.
33. Christophersen N.S., Helin K. Epigenetic control of embryonic stem cell fate. J. Exp. Med. 2010, 207:2287.
34. Cilensek Z.M., Yehiely F., Kular R.K., Deiss L.P. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-gamma, taxol and gamma-irradiation. Cancer Biol. Ther. 2002, 1:380.
35. Cloos P.A., Christensen J., Agger K., Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev. 2008, 22:1115.
36. Coe B.P., Lockwood W.W., Girard L., Chari R., Macaulay C., Lam S., Gazdar A.F., Minna J.D., Lam W.L. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br. J. Cancer 2006, 94:1927.
37. Dahl C., Gronbaek K., Guldberg P. Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin. Chim. Acta 2011, 412:831.
38. Damiani L.A., Yingling C.M., Leng S., Romo P.E., Nakamura J., Belinsky S.A. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res. 2008, 68:9005.
39. Darnton S.J., Hardie L.J., Muc R.S., Wild C.P., Casson A.G. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int. J. Cancer 2005, 115:351.
40. De Carvalho D.D., You J.S., Jones P.A. DNA methylation and cellular reprogramming. Trends Cell Biol. 2010, 20:609.
41. Destro A., Ceresoli G.L., Baryshnikova E., Garassino I., Zucali P.A., De V.F., Bianchi P., Morenghi E., Testori A., Alloisio M., Santoro A., Roncalli M. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Lung Cancer 2008, 59:369.
42. Dose A., Liokatis S., Theillet F.X., Selenko P., Schwarzer D. NMR profiling of histone deacetylase and acetyl-transferase activities in real time. ACS Chem. Biol. 2011, 6:419.
43. Du Z., Song J., Wang Y., Zhao Y., Guda K., Yang S., Kao H.Y., Xu Y., Willis J., Markowitz S.D., Sedwick D., Ewing R.M., Wang Z. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci. Signal. 2010, 3. ra80.
44. Egger G., Aparicio A.M., Escobar S.G., Jones P.A. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res. 2007, 67:346.
45. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1:239.
46. Eskeland R., Leeb M., Grimes G.R., Kress C., Boyle S., Sproul D., Gilbert N., Fan Y., Skoultchi A.I., Wutz A., Bickmore W.A. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol. Cell 2010, 38:452.
47. Fischer J.R., Ohnmacht U., Rieger N., Zemaitis M., Stoffregen C., Kostrzewa M., Buchholz E., Manegold C., Lahm H. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54:109.
48. Flores R.M., Zakowski M., Venkatraman E., Krug L., Rosenzweig K., Dycoco J., Lee C., Yeoh C., Bains M., Rusch V. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J. Thorac. Oncol. 2007, 2:957.
49. Friedman J.M., Liang G., Liu C.C., Wolff E.M., Tsai Y.C., Ye W., Zhou X., Jones P.A. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009, 69(6):2623.
50. Ge K. Epigenetic regulation of adipogenesis by histone methylation. Biochim. Biophys. Acta Jan 4 2012, [Electronic publication ahead of print].
51. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74:481.
52. Groeper C., Gambazzi F., Zajac P., Bubendorf L., Adamina M., Rosenthal R., Zerkowski H.R., Heberer M., Spagnoli G.C. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int. J. Cancer 2007, 120:337.
53. Guo Z.S., Hong J.A., Irvine K.R., Chen G.A., Spiess P.J., Liu Y., Zeng G., Wunderlich J.R., Nguyen D.M., Restifo N.P., Schrump D.S. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006, 66:1105.
54. Gure A.O., Chua R., Williamson B., Gonen M., Ferrera C.A., Gnjatic S., Ritter G., Simpson A.J., Chen Y.T., Old L.J., Altorki N.K. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 2005, 11:8055.
55. Ha K., Lee G.E., Palii S.S., Brown K.D., Takeda Y., Liu K., Bhalla K.N., Robertson K.D. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum. Mol. Genet. 2011, 20:126.
56. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574.
57. Hayami S., Yoshimatsu M., Veerakumarasivam A., Unoki M., Iwai Y., Tsunoda T., Field H.I., Kelly J.D., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol. Cancer 2010, 9:59.
58. Hayashi M., Tokuchi Y., Hashimoto T., Hayashi S., Nishida K., Ishikawa Y., Nakagawa K., Tsuchiya S., Okumura S., Tsuchiya E. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance. Anticancer. Res. 2001, 21:535.
59. He L.R., Liu M.Z., Li B.K., Jia W.H., Zhang Y., Liao Y.J., Chen Y.C., Zhang L.J., Guan X.Y., Zeng Y.X., Kung H.F., Xie D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int. J. Cancer 2010, 127(1):138.
60. He L.R., Liu M.Z., Li B.K., Rao H.L., Liao Y.J., Guan X.Y., Zeng Y.X., Xie D. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 2009, 9:461.
61. He X.T., Cao X.F., Ji L., Zhu B., Lv J., Wang D.D., Lu P.H., Cui H.G. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J. Gastroenterol. 2009, 15:2389.
62. He Y., Korboukh I., Jin J., Huang J. Targeting protein lysine methylation and demethylation in cancers. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:70.
63. Hernandez D.G., Nalls M.A., Gibbs J.R., Arepalli S., van der Brug M., Chong S., Moore M., Longo D.L., Cookson M., Traynor B.J., Singleton A. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum. Mol. Genet. 2011.
64. Hibi K., Nakamura H., Hirai A., Fujikake Y., Kasai Y., Akiyama S., Ito K., Takagi H. Loss of H19 imprinting in esophageal cancer. Cancer Res. 1996, 56:480.
65. Hirasawa R., Feil R. Genomic imprinting and human disease. Essays Biochem. 2010, 48:187.
66. Holm T.M., Jackson-Grusby L., Brambrink T., Yamada Y., Rideout W.M., Jaenisch R. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005, 8:275.
67. Hong J.A., Kang Y., Abdullaev Z., Flanagan P.T., Pack S.D., Fischette M.R., Adnani M.T., Loukinov D.I., Vatolin S., Risinger J.I., Custer M., Chen G.A., Zhao M., Nguyen D.M., Barrett J.C., Lobanenkov V.V., Schrump D.S. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005, 65:7763.
68. Howard G., Eiges R., Gaudet F., Jaenisch R., Eden A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2008, 27:404.
69. Hudlebusch H.R., Santoni-Rugiu E., Simon R., Ralfkiaer E., Rossing H.H., Johansen J.V., Jorgensen M., Sauter G., Helin K. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin. Cancer Res. 2011, 17:2919.
70. Hussain M., Rao M., Humphries A.E., Hong J.A., Liu F., Yang M., Caragacianu D., Schrump D.S. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 2009, 69:3570.
71. I K., Ko E., Kim Y., Cho E.Y., Han J., Park J., Kim K., Kim D.H., Shim Y.M. Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas. Cancer Epidemiol. Biomarkers Prev. 2010, 19:566.
72. Iliou M.S., Lujambio A., Portela A., Brustle O., Koch P., Andersson-Vincent P.H., Sundstrom E., Hovatta O., Esteller M. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics 2011, 6.
73. Ivanov S.V., Miller J., Lucito R., Tang C., Ivanova A.V., Pei J., Carbone M., Cruz C., Beck A., Webb C., Nonaka D., Testa J.R., Pass H.I. Genomic events associated with progression of pleural malignant mesothelioma. Int. J. Cancer 2009, 124:589.
74. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69.
75. Jin S.G., Jiang Y., Qiu R., Rauch T.A., Wang Y., Schackert G., Krex D., Lu Q., Pfeifer G.P. 5-Hydroxymethylcytosine Is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71:7360-7365.
76. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683.
77. Karbach J., Gnjatic S., Bender A., Neumann A., Weidmann E., Yuan J., Ferrara C.A., Hoffmann E., Old L.J., Altorki N.K., Jager E. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 2010, 126:909.
78. Kassambara A., Klein B., Moreaux J. MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem. Biophys. Res. Commun. 2009, 379:840.
79. Kassis E.S., Zhao M., Hong J.A., Chen G.A., Nguyen D.M., Schrump D.S. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J. Thorac. Cardiovasc. Surg. 2006, 131:298.
80. Kemp C.D., Rao M., Xi S., Inchauste S., Mani H., Fetsch P., Filie A.C., Zhang M., Hong J.A., Walker R., Zhu Y.J., Ripley R.T., Mathur A., Liu F., Yang M., Meltzer P.S., Marquez V.E., De R.A., Bueno R., Schrump D.S. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin. Cancer Res. 2012, 18:77-90.
81. Kikuchi J., Kinoshita I., Shimizu Y., Kikuchi E., Konishi J., Oizumi S., Kaga K., Matsuno Y., Nishimura M., Dosaka-Akita H. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010, 116:3015.
82. Kim H., Kwon Y.M., Kim J.S., Han J., Shim Y.M., Park J., Kim D.H. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006, 107:1042.
83. Kim J.S., Kim J.W., Han J., Shim Y.M., Park J., Kim D.H. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res. 2006, 66:4049.
84. Kim S.H., Lee S., Lee C.H., Lee M.K., Kim Y.D., Shin D.H., Choi K.U., Kim J.Y., Park d.Y., Sol M.Y. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 2009, 187:401.
85. Kim W., Kim R., Park G., Park J.W., Kim J.E. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J. Biol. Chem. 2012, 287:5588.
86. Kim Y., Park H., Park D., Lee Y.S., Choe J., Hahn J.H., Lee H., Kim Y.M., Jeoung D. Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J. Biol. Chem. 2010, 285:25957.
87. Kim Y.D., Park H.R., Song M.H., Shin D.H., Lee C.H., Lee M.K., Lee S.Y. Pattern of cancer/testis antigen expression in lung cancer patients. Int. J. Mol. Med. 2012, 29:656.
88. Kohda M., Hoshiya H., Katoh M., Tanaka I., Masuda R., Takemura T., Fujiwara M., Oshimura M. Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol. Carcinog. 2001, 31:184.
89. Kondo M., Matsuoka S., Uchida K., Osada H., Nagatake M., Takagi K., Harper J.W., Takahashi T., Elledge S.J., Takahashi T. Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene 1996, 12:1365.
90. Kondo M., Suzuki H., Ueda R., Osada H., Takagi K., Takahashi T., Takahashi T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995, 10:1193.
91. Lam L.T., Pickeral O.K., Peng A.C., Rosenwald A., Hurt E.M., Giltnane J.M., Averett L.M., Zhao H., Davis R.E., Sathyamoorthy M., Wahl L.M., Harris E.D., Mikovits J.A., Monks A.P., Hollingshead M.G., Sausville E.A., Staudt L.M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001, 2. RESEARCH0041.
92. Langer R., Mutze K., Becker K., Feith M., Ott K., Hofler H., Keller G. Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. J. Clin. Pathol. 2010, 63:994.
93. Lee E.J., Lee B.B., Han J., Cho E.Y., Shim Y.M., Park J., Kim D.H. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int. J. Cancer 2008, 123:2073.
94. Lee J.S., Smith E., Shilatifard A. The language of histone crosstalk. Cell 2010, 142:682.
95. Li B., Wang B., Niu L.J., Jiang L., Qiu C.C. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics 2011, 6:307.
96. Lin R.K., Hsieh Y.S., Lin P., Hsu H.S., Chen C.Y., Tang Y.A., Lee C.F., Wang Y.C. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest. 2010, 120:521.
97. Lin R.K., Hsu C.H., Wang Y.C. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 2007, 18:1157.
98. Lin R.K., Hsu H.S., Chang J.W., Chen C.Y., Chen J.T., Wang Y.C. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007, 55:205.
99. Ling Y., Huang G., Fan L., Wei L., Zhu J., Liu Y., Zhu C., Zhang C. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J. Clin. Pathol. 2011, 64:246.
100. Liu F., Killian J.K., Yang M., Walker R.L., Hong J.A., Zhang M., Davis S., Zhang Y., Hussain M., Xi S., Rao M., Meltzer P.A., Schrump D.S. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010, 29:3650.
101. Liu W.L., Guo X.Z., Zhang L.J., Wang J.Y., Zhang G., Guan S., Chen Y.M., Kong Q.L., Xu L.H., Li M.Z., Song L.B., Zeng M.S. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer 2010, 10:467.
102. Loriot A., Parvizi G.K., Reister S., De S.C. Silencing of cancer-germline genes in human preimplantation embryos: evidence for active de novo DNA methylation in stem cells. Biochem. Biophys. Res. Commun. 2012, 417:187-191.
103. Lu C., Soria J.C., Tang X., Xu X.C., Wang L., Mao L., Lotan R., Kemp B., Bekele B.N., Feng L., Hong W.K., Khuri F.R. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J. Clin. Oncol. 2004, 22:4575.
104. Lu J., He M.L., Wang L., Chen Y., Liu X., Dong Q., Chen Y.C., Peng Y., Yao K.T., Kung H.F., Li X.P. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71(1):225.
105. Luszczek W., Cheriyath V., Mekhail T.M., Borden E.C. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol. Cancer Ther. 2010, 9:2309.
106. Marcar L., Maclaine N.J., Hupp T.R., Meek D.W. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 2010, 70:10362.
107. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 2006, 66:3541.
108. Melloni G., Ferreri A.J., Russo V., Gattinoni L., Arrigoni G., Ceresoli G.L., Zannini P., Traversari C. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol. Rep. 2004, 12:145.
109. Mills A.A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 2010, 10:669.
110. Minamiya Y., Ono T., Saito H., Takahashi N., Ito M., Motoyama S., Ogawa J. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol. 2010, 31:533.
111. Minamiya Y., Ono T., Saito H., Takahashi N., Ito M., Motoyama S., Ogawa J. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol. 2010, 31:533.
112. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997, 8:358.
113. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., Rodolfo M., Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11160.
114. Morey L., Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem. Sci. 2010, 35:323.
115. Nakagawa K., Noguchi Y., Uenaka A., Sato S., Okumura H., Tanaka M., Shimono M., Ali Eldib A.M., Ono T., Ohara N., Yoshino T., Yamashita K., Tsunoda T., Aoe M., Shimizu N., Nakayama E. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin. Cancer Res. 2005, 11:5496.
116. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769.
117. Nakata S., Sugio K., Uramoto H., Oyama T., Hanagiri T., Morita M., Yasumoto K. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 2006, 106:2190.
118. Nguyen D.M., Schrump W.D., Chen G.A., Tsai W., Nguyen P., Trepel J.B., Schrump D.S. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res. 2004, 10:1813.
119. Nottke A., Colaiacovo M.P., Shi Y. Developmental roles of the histone lysine demethylases. Development 2009, 136:879.
120. Oka M., Meacham A.M., Hamazaki T., Rodic N., Chang L.J., Terada N. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine. Oncogene 2005, 24:3091.
121. Ono T., Kurashige T., Harada N., Noguchi Y., Saika T., Niikawa N., Aoe M., Nakamura S., Higashi T., Hiraki A., Wada H., Kumon H., Old L.J., Nakayama E. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3282.
122. Osada H., Tatematsu Y., Saito H., Yatabe Y., Mitsudomi T., Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer 2004, 112:26.
123. Otterson G.A., Hodgson L., Pang H., Vokes E.E. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J. Thorac. Oncol. 2010, 5:1644.
124. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 2008, 28:752.
125. Parmigiani R.B., Bettoni F., Vibranovski M.D., Lopes M.H., Martins W.K., Cunha I.W., Soares F.A., Simpson A.J., de Souza S.J., Camargo A.A. Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18066.
126. Por E., Byun H.J., Lee E.J., Lim J.H., Jung S.Y., Park I., Kim Y.M., Jeoung D.I., Lee H. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J. Biol. Chem. 2010, 285:14475.
127. Rai K., Sarkar S., Broadbent T.J., Voas M., Grossmann K.F., Nadauld L.D., Dehghanizadeh S., Hagos F.T., Li Y., Toth R.K., Chidester S., Bahr T.M., Johnson W.E., Sklow B., Burt R., Cairns B.R., Jones D.A. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell 2010, 142:930.
128. Ramalingam S.S., Maitland M.L., Frankel P., Argiris A.E., Koczywas M., Gitlitz B., Thomas S., Espinoza-Delgado I., Vokes E.E., Gandara D.R., Belani C.P. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:56.
129. Rao M., Chinnasamy N., Hong J.A., Zhang Y., Zhang M., Xi S., Liu F., Marquez V.E., Morgan R.A., Schrump D.S. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 2011, 71:4192.
130. Renaud S., Loukinov D., Alberti L., Vostrov A., Kwon Y.W., Bosman F.T., Lobanenkov V., Benhattar J. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res. 2011, 39:862-873.
131. Reynolds P.A., Sigaroudinia M., Zardo G., Wilson M.B., Benton G.M., Miller C.J., Hong C., Fridlyand J., Costello J.F., Tlsty T.D. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J. Biol. Chem. 2006, 281:24790.
132. Rizzo S., Hersey J.M., Mellor P., Dai W., Santos-Silva A., Liber D., Luk L., Titley I., Carden C.P., Box G., Hudson D.L., Kaye S.B., Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 2011, 10:325.
133. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917.
134. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., Yamakawa Y., Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46:171.
135. Sato M., Shames D.S., Gazdar A.F., Minna J.D. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2007, 2:327.
136. Sauvageau M., Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299.
137. Sawan C., Herceg Z. Histone modifications and cancer. Adv. Genet. 2010, 70:57.
138. Sawarkar R., Paro R. Interpretation of developmental signaling at chromatin: the Polycomb perspective. Dev. Cell 2010, 19:651.
139. Schar P., Fritsch O. DNA repair and the control of DNA methylation. Prog. Drug Res. 2011, 67:51.
140. Scharf A.N., Imhof A. Every methyl counts - epigenetic calculus. FEBS Lett. 2011, 585:2001-2007.
141. Schrump D.S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 2009, 15:3947.
142. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., Hancox A., Hong J.A., Chen G.A., Kruchin E., Wright J.J., Rosing D.R., Sparreboom A., Figg W.D., Steinberg S.M. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res. 2008, 14:188.
143. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., Hancox A., Hong J.A., Chen G.A., Pishchik V., Figg W.D., Murgo A.J., Steinberg S.M. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 2006, 12:5777.
144. Schrump D.S., Hong J.A., Nguyen D.M. Utilization of chromatin remodeling agents for lung cancer therapy. Cancer J. 2007, 13:56.
145. Schrump D.S., Nguyen D.M. Targeting the epigenome for the treatment and prevention of lung cancer. Semin. Oncol. 2005, 32:488.
146. Schultz-Thater E., Piscuoglio S., Iezzi G., Le M.C., Zajac P., Carafa V., Terracciano L., Tornillo L., Spagnoli G.C. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int. J. Cancer 2011, 129:1137.
147. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174:1619.
148. Seng T.J., Currey N., Cooper W.A., Lee C.S., Chan C., Horvath L., Sutherland R.L., Kennedy C., McCaughan B., Kohonen-Corish M.R. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br. J. Cancer 2008, 99:375.
149. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212.
150. Simao T.A., Simoes G.L., Ribeiro F.S., Cidade D.A., Andreollo N.A., Lopes L.R., Macedo J.M., Acatauassu R., Teixeira A.M., Felzenszwalb I., Pinto L.F., Albano R.M. Lower expression of p14ARF and p16INK4a correlates with higher DNMT3B expression in human oesophageal squamous cell carcinomas. Hum. Exp. Toxicol. 2006, 25:515.
151. Spange S., Wagner T., Heinzel T., Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41:185.
152. Stevenson B.J., Iseli C., Panji S., Zahn-Zabal M., Hide W., Old L.J., Simpson A.J., Jongeneel C.V. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics 2007, 8:129.
153. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., Arand M., Knuth A., Old L.J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998, 187:1349.
154. Suva M.L., Riggi N., Janiszewska M., Radovanovic I., Provero P., Stehle J.C., Baumer K., Le Bitoux M.A., Marino D., Cironi L., Marquez V.E., Clement V., Stamenkovic I. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009, 69:9211.
155. Ting D.T., Lipson D., Paul S., Brannigan B.W., Akhavanfard S., Coffman E.J., Contino G., Deshpande V., Iafrate A.J., Letovsky S., Rivera M.N., Bardeesy N., Maheswaran S., Haber D.A. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 2011, 331:593-596.
156. Toh Y., Yamamoto M., Endo K., Ikeda Y., Baba H., Kohnoe S., Yonemasu H., Hachitanda Y., Okamura T., Sugimachi K. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol. Rep. 2003, 10:333.
157. Traynor A.M., Dubey S., Eickhoff J.C., Kolesar J.M., Schell K., Huie M.S., Groteluschen D.L., Marcotte S.M., Hallahan C.M., Weeks H.R., Wilding G., Espinoza-Delgado I., Schiller J.H. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J. Thorac. Oncol. 2009, 4:522.
158. Tzao C., Tung H.J., Jin J.S., Sun G.H., Hsu H.S., Chen B.H., Yu C.P., Lee S.C. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod. Pathol. 2009, 22:252.
159. Vallbohmer D., Brabender J., Yang D., Schneider P.M., Metzger R., Danenberg K.D., Holscher A.H., Danenberg P.V. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin. Lung Cancer 2006, 8:39.
160. Van Den Broeck A., Brambilla E., Moro-Sibilot D., Lantuejoul S., Brambilla C., Eymin B., Khochbin S., Gazzeri S. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 2008, 14:7237.
161. Vatolin S., Abdullaev Z., Pack S.D., Flanagan P.T., Custer M., Loukinov D.I., Pugacheva E., Hong J.A., Morse H., Schrump D.S., Risinger J.I., Barrett J.C., Lobanenkov V.V. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res. 2005, 65:7751.
162. Vrzalikova K., Skarda J., Ehrmann J., Murray P.G., Fridman E., Kopolovic J., Knizetova P., Hajduch M., Klein J., Kolek V., Radova L., Kolar Z. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J. Cancer Res. Clin. Oncol. 2008, 134:1037.
163. Vu T.H., Nguyen A.H., Hoffman A.R. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum. Mol. Genet. 2010, 19:901.
164. Wargo J.A., Robbins P.F., Li Y., Zhao Y., El-Gamil M., Caragacianu D., Zheng Z., Hong J.A., Downey S., Schrump D.S., Rosenberg S.A., Morgan R.A. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 2009, 58:383.
165. Watanabe H., Soejima K., Yasuda H., Kawada I., Nakachi I., Yoda S., Naoki K., Ishizaka A. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int. 2008, 8:15.
166. Weiser T.S., Guo Z.S., Ohnmacht G.A., Parkhurst M.L., Tong-On P., Marincola F.M., Fischette M.R., Yu X., Chen G.A., Hong J.A., Stewart J.H., Nguyen D.M., Rosenberg S.A., Schrump D.S. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 2001, 24:151.
167. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157.
168. Wienholz B.L., Kareta M.S., Moarefi A.H., Gordon C.A., Ginno P.A., Chedin F. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet. 2010, 6.
169. Wu D., Xiong L., Wu S., Jiang M., Lian G., Wang M. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer 2012, 76:106.
170. Xing J., Stewart D.J., Gu J., Lu C., Spitz M.R., Wu X. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br. J. Cancer 2008, 98:1716.
171. Xiong J., Epstein R.J. Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. Mol. Cancer Ther. 2009, 8:779.
172. Yamada A., Fujii S., Daiko H., Nishimura M., Chiba T., Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int. J. Oncol. 2011, 38:345.
173. Yamada Y., Jackson-Grusby L., Linhart H., Meissner A., Eden A., Lin H., Jaenisch R. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13580.
174. Yanagawa N., Tamura G., Oizumi H., Endoh M., Motoyama T. MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer. Res. 2011, 31:171.
175. Yanagawa N., Tamura G., Oizumi H., Kanauchi N., Endoh M., Sadahiro M., Motoyama T. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007, 58:131.
176. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., Gravekamp C., Setaluri V., Peters N., Hoffmann F.M., Peng H., Ivanov A.V., Simpson A.J., Longley B.J. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 2007, 67:9954.
177. Yeow W.S., Ziauddin M.F., Maxhimer J.B., Shamimi-Noori S., Baras A., Chua A., Schrump D.S., Nguyen D.M. Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br. J. Cancer 2006, 94:1436.
178. Yi J.M., Kim H.S. Molecular phylogenetic analysis of the human endogenous retrovirus E (HERV-E) family in human tissues and human cancers. Genes Genet. Syst. 2007, 82:89.
179. Yoon K.A., Hwangbo B., Kim I.J., Park S., Kim H.S., Kee H.J., Lee J.E., Jang Y.K., Park J.G., Lee J.S. Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis 2006, 27:2217.
180. Yoshimura H., Takemoto K. Effect of cigarette smoking and/or N-bis(2-hydroxypropyl)nitrosamine (DHPN) on the development of lung and pleural tumors in rats induced by administration of asbestos. Sangyo Igaku 1991, 33:81.
181. Yoshino M., Suzuki M., Tian L., Moriya Y., Hoshino H., Okamoto T., Yoshida S., Shibuya K., Yoshino I. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int. J. Oncol. 2009, 35:1201.
182. Yost J.M., Korboukh I., Liu F., Gao C., Jin J. Targets in epigenetics: inhibiting the methyl writers of the histone code. Curr. Chem. Genomics 2011, 5:72.
183. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 2002, 94:504.
184. Yu X.D., Wang S.Y., Chen G.A., Hou C.M., Zhao M., Hong J.A., Nguyen D.M., Schrump D.S. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J. 2007, 13:105.
185. Zauderer M.G., Krug L.M. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr. Treat. Options Oncol. 2011.
186. Zhai R., Chen F., Liu G., Su L., Kulke M.H., Asomaning K., Lin X., Heist R.S., Nishioka N.S., Sheu C.C., Wain J.C., Christiani D.C. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J. Clin. Oncol. 2010, 28:2445.
187. Zhang J.G., Guo J.F., Liu D.L., Liu Q., Wang J.J. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J. Thorac. Oncol. 2009, 4:161-166.
188. Zhang W., Peyton M., Xie Y., Soh J., Minna J.D., Gazdar A.F., Frenkel E.P. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J. Thorac. Oncol. 2009, 4:161.
189. Zhang X., Wen H., Shi X. Lysine methylation: beyond histones. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:14.
190. Zhang X.Y., Dong Q.G., Huang J.S., Huang A.M., Shi C.L., Jin B., Sha H.F., Feng J.X., Geng Q., Zhou J., Xu H.L., Han B.H. The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J. Surg. Oncol. 2010, 102:856.
191. Zhang Y., Miao Y., Yi J., Wang R., Chen L. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin. Lung Cancer 2010, 11:264.
192. Zhao R., DeCoteau J.F., Geyer C.R., Gao M., Cui H., Casson A.G. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis 2009, 30:2117.